BIOIO
BIOIO is a St. Louis-based longevity biotechnology company using its MOAT mechanism-of-action platform to identify drug candidates targeting aging pathways. Its pipeline includes BIOIO-1001, a first-in-class insulin sensitizer targeting Sirt3, and BIOIO-2001, targeting sphingolipid biosynthesis.
- Company typePrivate
- Founded2019
- HeadquartersSt Louis, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What BIOIO does
BIOIO, Inc. is a St. Louis-based longevity biotechnology company founded in 2019 that develops gerotherapies — drugs targeting core molecular mechanisms of aging — through its proprietary MOAT (Mechanism of Action Technologies) platform. MOAT is a mechanism-of-action-driven clinical indication prediction engine that combines experimental multi-omics with cell fitness-based, unbiased genome-wide screening, positioning it as a higher signal-to-noise approach to elucidating how small molecules work. MOAT 2.0, the second-generation platform, adds AI-generated virtual genomic screening and an in silico Gene2Drug module that has been validated in models of rheumatoid arthritis.
BIOIO's pipeline comprises two lead drug candidates: BIOIO-1001, a first-in-class insulin sensitizer that modulates Sirtuin 3 (Sirt3) via an NAD+-dependent pathway, inducing fatty acid oxidation without engaging PPARs and thereby bypassing limitations of fibrates, glitazars, and thiazolidinediones for type 2 diabetes; and BIOIO-2001, which targets sphingolipid biosynthesis (the SPT enzyme) and has been linked to diabetic neuropathy through a 2025 collaboration with University Hospital of Zurich. Both compounds are positioned as bona fide gerotherapies impinging on multiple hallmarks of aging, enabling a "pipeline-in-a-pill" strategy of multi-indication application per asset.
The company's commercial model is pre-revenue and built around licensing, partnerships, and grant funding rather than product sales. Strategic relationships include a 2020 oncology co-development partnership with SPARC (Sun Pharma), a 2022 LabDAO partnership to virtualize drug discovery, ongoing research collaborations with Washington University in St. Louis, and IP-NFT-structured funding from VitaDAO for BIOIO-2001. The company is led by founders Tim Peterson, PhD (CEO; MIT/Harvard HHMI-trained, former WashU Assistant Professor) and Joppe Nieuwenhuis, PhD (COO; Netherlands Cancer Institute-trained, ex-Rejuveron and Batavia Biosciences). Cumulative dilutive and non-dilutive funding is approximately $20M, anchored by NIH STTR grants, longevity-focused VCs (Lifespan Vision Ventures, quadraScope), and the Missouri Technology Corporation, which has backed the company in both January 2024 ($2.2M) and January 2026 ($5.8M) IDEA FUND cycles.
BIOIO firmographics
Firmographics- Name
- BIOIO
- Legal name
- BIOIO, Inc.
- Website
- https://bioio.tech
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BIOIO is a St. Louis-based longevity biotechnology company using its MOAT mechanism-of-action platform to identify drug candidates targeting aging pathways. Its pipeline includes BIOIO-1001, a first-in-class insulin sensitizer targeting Sirt3, and BIOIO-2001, targeting sphingolipid biosynthesis.
- Ownership category
- akta.pro rank
BIOIO industry classification
Industry- Product category
- Drug Discovery & Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industry
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)
Keywords
Where BIOIO is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BIOIO business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Drug Development & Licensing: BIOIO develops proprietary drug candidates (BIOIO-1001, BIOIO-2001) through its MOAT platform and plans to commercialize through licensing deals with pharmaceutical partners or through continued development toward clinical trials.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
BIOIO product offering
Product offeringCore offering
BIOIO is a longevity biotechnology company that develops proprietary drug candidates (gerotherapies) for cancer, metabolic disease, and aging-related conditions using its MOAT (Mechanism of Action Technologies) platform. The company combines experimental multi-omics approaches with AI-driven computational analysis to predict drug mechanisms and identify clinical indications, advancing first-in-class candidates such as BIOIO-1001 (an insulin sensitizer targeting Sirt3) and BIOIO-2001 (a sphingolipid biosynthesis inhibitor). BIOIO plans to commercialize its assets through licensing deals and strategic partnerships with pharmaceutical and biotech companies.
Product overview
BIOIO is a longevity biotechnology company developing gerotherapies that target aging at its molecular core to extend health-span and longevity. The company's platform consists of the MOAT (Mechanism of Action Technologies) platform, which combines experimental multi-omics approaches with computational AI-driven analysis to predict clinical indications and identify drug mechanisms. MOAT 2.0 represents the second generation capable of virtual genomic screening. The pipeline includes two drug candidates: BIOIO-1001, a first-in-class insulin sensitizer targeting Sirtuin 3 for metabolic disease treatment, and BIOIO-2001, targeting sphingolipid biosynthesis for diabetic neuropathy. Both compounds act on lipid metabolism and impinge on multiple hallmarks of aging, creating a 'pipeline in a pill' approach where each asset can be applied to multiple clinical indications.
Differentiator
Problem solved
Functional benefit
Products and services
- MOAT Platform A MoA-driven clinical indication prediction engine combining experimental multi-omics approaches with computational analysis and cell fitness-based unbiased genome-wide screening to identify small molecule mechanisms of action and predict clinical applications. Designed for pharmaceutical and biotech partners seeking novel drug candidates and MoA insights.
- MOAT 2.0 Second-generation platform that performs virtual genomic screens using AI-generated predictions to identify mechanism of action and clinical indications, significantly reducing time and cost compared to experimental-only approaches. Validated through the Gene2Drug module for chemical mimic identification.
- BIOIO-1001 A first-in-class insulin sensitizer that targets Sirtuin 3 (Sirt3) via NAD+-dependent pathway modulation, inducing fatty acid oxidation without relying on PPARs. Developed for the treatment of type 2 diabetes mellitus by addressing insulin resistance at its root cause.
- BIOIO-2001 A drug candidate targeting the sphingolipid biosynthesis pathway, addressing lipid metabolism and multiple hallmarks of aging. Funded by VitaDAO via Molecule's IP-NFT framework. Indicated for diabetic neuropathy and related metabolic conditions.
Quantifiable outcome
- Insulin sensitization through NAD+-dependent Sirt3 modulation without PPAR dependency
- +1 more outcomes
Companies that use BIOIO
Customer profileSegments2 records
Ideal customer profiles2 records
BIOIO technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
BIOIO partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- SPARC (Sun Pharma)corePartnership with Sun Pharma's SPARC initiative to use BIOIO's MOAT platform for oncology drug development, announced February 2020.
- Washington University (WashU)coreOngoing research collaboration with WashU scientists including Yousef Abu Amer (arthritis research), Brian Finck and Kyle McCommis (BIOIO-1001 manuscript), and Gabriel Mbalaviele (TMEM178/NLRP3 research). WashU is the academic home of multiple BIOIO team members.
- University Hospital of ZurichminorCollaboration in November 2025 where MOAT found that Very long-chain fatty acids drive 1-deoxySphingolipid toxicity, a driver of Diabetic Neuropathy targeted by BIOIO-2001.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
BIOIO competitors and assessment
Company assessmentDirect peers
- Insilico Medicine: AI-driven drug discovery company combining generative biology with longevity/aging-disease pipeline. Closest direct peer to BIOIO given shared platform-plus-therapeutics model and explicit focus on aging-related indications.
- Recursion Pharmaceuticals: Platform biotech combining high-throughput biology with ML to discover new therapeutics at scale. Directly comparable to BIOIO's MOAT approach of using systematic experimental data plus computation to drive indication prediction.
- Schrödinger: Computational chemistry and predictive modeling platform used for drug discovery by pharma clients and internal programs. Comparable to BIOIO's MOAT 2.0 virtual screening and platform-licensing model.
- Insitro: ML-driven drug discovery company combining induced pluripotent stem cell biology with machine learning to identify targets and predict indications. Directly comparable platform-plus-therapeutics approach to BIOIO's MOAT.
- Atomwise: AI-driven small molecule discovery platform that partners with pharma and develops internal pipeline. Comparable to BIOIO's MOAT 2.0 virtual screening and pharma-licensing go-to-market.
Broad incumbents
- Altos Labs: Well-capitalized longevity biotech pursuing cellular rejuvenation programming. Comparable thematic adjacency to BIOIO's gerotherapy framing, but a much larger and broader incumbent in the same longevity space.
- Calico Life Sciences: Alphabet-backed longevity R&D organization pursuing fundamental biology of aging and age-related disease. Broad incumbent in the same aging/gerotherapy thematic category as BIOIO.
Emerging players
- NewLimit: Early-stage longevity biotech applying epigenetic reprogramming to aged cell types. Comparable as a peer emerging-player in the longevity/gerotherapy category where BIOIO also competes for talent and capital.
- Loyal for Dogs: Longevity therapeutics company developing drugs to extend dog healthspan, with FDA engagement on aging as an indication. Useful peer for understanding regulatory framing of gerotherapy — overlapping theme but different species focus.
Others
- VitaDAO: Decentralized longevity research DAO that funded BIOIO-2001 via IP-NFT. Included as an ecosystem/funder peer rather than a competitor; reflects the alternative capital channel BIOIO accesses.
Market position
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BIOIO social profiles
Digital presenceBIOIO financial estimates
Financial estimateRevenue estimate
Valuation estimate
BIOIO leadership team
Management profileNumber of profiles
Profiles2 records
BIOIO funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BIOIO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BIOIO
What does BIOIO do?
BIOIO is a longevity biotechnology company that develops proprietary drug candidates (gerotherapies) for cancer, metabolic disease, and aging-related conditions using its MOAT (Mechanism of Action Technologies) platform. The company combines experimental multi-omics approaches with AI-driven computational analysis to predict drug mechanisms and identify clinical indications, advancing first-in-class candidates such as BIOIO-1001 (an insulin sensitizer targeting Sirt3) and BIOIO-2001 (a sphingolipid biosynthesis inhibitor). BIOIO plans to commercialize its assets through licensing deals and strategic partnerships with pharmaceutical and biotech companies.
Is BIOIO a public or private company?
BIOIO is a private company. It is classified as venture growth investor backed and is currently operating.
When was BIOIO founded?
BIOIO was founded in 2019. It employs 1 to 10 people.
Where is BIOIO based?
BIOIO is headquartered in St Louis, United States, in the North America region.
How does BIOIO make money?
One revenue line is on record: drug Development & Licensing.
Who are BIOIO's main competitors?
Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, Insitro and Atomwise. Broad incumbents are Altos Labs and Calico Life Sciences. Emerging players are NewLimit and Loyal for Dogs. VitaDAO is listed as an others.
Does BIOIO have an API?
No public API is recorded for BIOIO.
What industry is BIOIO in?
BIOIO's product category is Drug Discovery & Development. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.